期刊
HEPATOLOGY COMMUNICATIONS
卷 5, 期 5, 页码 736-748出版社
JOHN WILEY & SONS LTD
DOI: 10.1002/hep4.1611
关键词
-
资金
- National Natural Science Foundation of China [31671945]
- China Scholarship Council [201706350184, 201706180048]
SGLT2 inhibitors can protect individuals with NAFLD from severe complications by inhibiting renal glucose reabsorption and other processes that contribute to liver dysfunction.
Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver diseases by inhibiting SGLT2-mediated renal glucose reabsorption and inducing glycosuria. Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease, resulting in severe liver dysfunction. During the progression of NAFLD, there are some hallmark complications, including lipid metabolism disorders, inflammation induction, and hepatocyte death. Herein, we review several SGLT2 inhibitors that are capable of protecting individuals with NAFLD from severe complications by inhibiting de novo lipogenesis, oxidative responses, inflammation induction, and hepatocyte death.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据